Drug Trial Radar · NCT05628870
A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer
Last checked: Nov 20, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
102
Planned (sponsor's estimate)
Start
Feb 7, 2023
Primary completion
Jun 2025
Study completion Jun 30, 2025
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the safety and tolerability of HRS-1358 monotherapy or combination with Dalpiciclib Isethionate Tablets in patients with metastatic or locally advanced breast cancer in order to estimate the Dose-Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and select the Recommended Phase 2 Dose (RP2D).
Conditions
- Breast Cancer
Interventions
HRS-1358Drug
HRS-1358 or combination with Dalpiciclib Isethionate Tablets will be administered daily orally in continuous dosing over 28-day cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limited Toxicities (DLTs)Time frame: up to 28 days
- Maximum tolerated doseTime frame: up to 28 days
- RP2DTime frame: Change From Baseline at 28 days
- Incidence and severity of adverse events (AEs)/serious adverse events (SAEs)Time frame: up to 30 days after the last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.